Right ventricular assist and prostacyclin infusion for allograft failure in the presence of high pulmonary vascular resistance

J Heart Transplant. 1990 Mar-Apr;9(2):136-41.

Abstract

The presence of high pulmonary vascular resistance (PVR) greater than 4 Wood units contributes to significant early posttransplant mortality, and remains a negative predictor of long-term survival. Current trends have been toward exclusion of the recipient with high PVR from the orthotopic procedure; elective heterotopic allograft placement is increasingly advocated. A patient with a PVR of 6 Wood units underwent orthotopic transplantation; the cardiac allograft from a 12 kg heavier donor was implanted after an ischemic time of 115 minutes. Early graft failure at 4 hours and subsequent cardiac arrest were followed by reinstitution of cardiopulmonary bypass, during which time optimal pharmacologic manipulation of the pulmonary vasculature was undertaken, including the use of high-dose prostacyclin. Refractory right heart failure indicated the requirement for right ventricular assistance (RVA) for patient survival. RVA with a Bio-Medicus pump was instituted in association with high-dose prostacyclin; an intraaortic balloon pump was inserted 12 hours later. Maintenance immunosuppression consisted of cyclosporine and azathioprine alone. RVA was maintained for 3 days; during this time the patient was totally pump dependent. Over an 18-hour period the patient was weaned and successfully withdrawn from RVA. Intraaortic balloon pump counterpulsation and the prostacyclin infusion were continued for 6 and 10 days, respectively. The clinical implications of the various interventions that resulted in the patient's survival are discussed.

Publication types

  • Case Reports

MeSH terms

  • Cardiac Output, Low / etiology
  • Cardiac Output, Low / therapy*
  • Epoprostenol / therapeutic use*
  • Heart Transplantation*
  • Heart-Assist Devices*
  • Humans
  • Male
  • Middle Aged
  • Postoperative Complications / therapy*
  • Pulmonary Artery / physiopathology*
  • Vascular Resistance

Substances

  • Epoprostenol